SABCS 2023 | Highlights from SABCS 2023: the future of immunotherapy in higher-risk ER+ breast cancer

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the highlights from the 2023 San Antonio Breast Cancer Symposium (SABCS), with a focus on investigating pathological complete response (pCR) rates in patients with higher-risk ER+ breast cancer treated with immunotherapy. Dr Hamilton highlights two abstracts, which demonstrated that there was greater pCR rates observed in patients with high-risk ER+ breast cancer treated with immunotherapy. This interview took place at the 2023 SABCS congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.